Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Ferrari

Showing results (221-230 of 547) with videos related to

Pageof 55
Sort By:
Journal of Molecular and Cellular Cardiology|November 4, 2004
Co-expression and modulation of neuronal and endothelial nitric oxide synthase in human endothelial cellsTiziana Bachetti, Laura Comini, Salvatore Curello, et al.
Italian Heart Journal : Official Journal of the Italian Federation of Cardiology|February 21, 2006
[Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI]Roberto Ferrari, Kristaq Papa, Palmira Bernocchi, et al.
Journal of Thrombosis and Thrombolysis|February 17, 2010
Poor response to clopidogrel: current and future options for its managementGianluca Campo, Luca Fileti, Marco Valgimigli, et al.
Pacing and Clinical Electrophysiology : PACE|January 7, 2011
Different image integration modalities to guide AF ablation: impact on procedural and fluoroscopy timesClaudio Pratola, Elisa Baldo, Paolo Artale, et al.
Biomedicines|August 27, 2021
Well-Known and Novel Players in Endothelial Dysfunction: Updates on a Notch(ed) LandscapeFrancesca Fortini, Francesco Vieceli Dalla Sega, Luisa Marracino, et al.
Journal of the American College of Cardiology|July 6, 2004
The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE TrialMarco Valgimigli, Gianfranco Percoco, Dario Barbieri, et al.
Platelets|June 2, 2011
Genetic determinants of on-clopidogrel high platelet reactivityGianluca Campo, Matteo Miccoli, Matteo Tebaldi, et al.
Circulation. Cardiovascular Quality and Outcomes|December 24, 2015
Quality of Life With Ivabradine in Patients With Angina Pectoris: The Study Assessing the Morbidity-Mortality Benefits of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease Quality of Life SubstudyMichal Tendera, Olivier Chassany, Roberto Ferrari, et al.
Journal of the American College of Cardiology|February 2, 2010
Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness: the 3T/2R (Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel)Gianluca Campo, Marco Valgimigli, Alice Frangione, et al.
European Journal of Internal Medicine|June 6, 2021
Combining New Classes of Drugs for HFrEF: from Trials to Clinical PracticeGianfranco Sinagra, Linda Pagura, Davide Stolfo, et al.
Pageof 55

Showing results (221-230 of 547) with videos related to

Sort By:
Pageof 55
Journal of Molecular and Cellular Cardiology|November 4, 2004
Co-expression and modulation of neuronal and endothelial nitric oxide synthase in human endothelial cellsTiziana Bachetti, Laura Comini, Salvatore Curello, et al.
Italian Heart Journal : Official Journal of the Italian Federation of Cardiology|February 21, 2006
[Angiotensin-converting enzyme inhibitors in patients with preserved left ventricular function: from EUROPA to PREAMI]Roberto Ferrari, Kristaq Papa, Palmira Bernocchi, et al.
Journal of Thrombosis and Thrombolysis|February 17, 2010
Poor response to clopidogrel: current and future options for its managementGianluca Campo, Luca Fileti, Marco Valgimigli, et al.
Pacing and Clinical Electrophysiology : PACE|January 7, 2011
Different image integration modalities to guide AF ablation: impact on procedural and fluoroscopy timesClaudio Pratola, Elisa Baldo, Paolo Artale, et al.
Biomedicines|August 27, 2021
Well-Known and Novel Players in Endothelial Dysfunction: Updates on a Notch(ed) LandscapeFrancesca Fortini, Francesco Vieceli Dalla Sega, Luisa Marracino, et al.
Journal of the American College of Cardiology|July 6, 2004
The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE TrialMarco Valgimigli, Gianfranco Percoco, Dario Barbieri, et al.
Platelets|June 2, 2011
Genetic determinants of on-clopidogrel high platelet reactivityGianluca Campo, Matteo Miccoli, Matteo Tebaldi, et al.
Circulation. Cardiovascular Quality and Outcomes|December 24, 2015
Quality of Life With Ivabradine in Patients With Angina Pectoris: The Study Assessing the Morbidity-Mortality Benefits of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease Quality of Life SubstudyMichal Tendera, Olivier Chassany, Roberto Ferrari, et al.
Journal of the American College of Cardiology|February 2, 2010
Evaluation of platelet inhibition by tirofiban in patients stratified according to aspirin and clopidogrel responsiveness: the 3T/2R (Tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel)Gianluca Campo, Marco Valgimigli, Alice Frangione, et al.
European Journal of Internal Medicine|June 6, 2021
Combining New Classes of Drugs for HFrEF: from Trials to Clinical PracticeGianfranco Sinagra, Linda Pagura, Davide Stolfo, et al.
Pageof 55